More Patients Should Receive Cardiac Resynchronization Therapy, Heart Groups Say
This article was originally published in The Gray Sheet
Executive Summary
In revised practice guidelines released Sept. 10, the American Heart Association, the Heart Rhythm Society and the American College of Cardiology Foundation say new evidence shows that many patients with mild heart failure can benefit from cardiac resynchronization devices.
You may also be interested in...
Medtronic-Sponsored Economic Analysis Supports CRT Devices As Cost-Effective
New analysis from the Medtronic-sponsored REVERSE trial shows that patients with mild heart failure receiving CRT therapy had an ICER (incremental cost effectiveness ratio) of $8,840 per QALY, compared to those not receiving CRT.
Cardiac Resynchronization Is Inappropriate For Patients With Short QRS, Study Confirms
The trial shows that cardiac-resynchronization therapy does not reduce mortality or hospitalizations in heart failure patients with a QRS duration shorter than 130 milliseconds on an electrocardiogram. The finding essentially affirms current guidelines, but it does not support off-label practice by some cardiologists who had hoped CRT could be useful in a broader patient population.
CDRH Launches ‘Health Of Women’ Program; Research Agenda To Focus On Ortho, Cardio Devices
The device center plans to develop a research roadmap to explore sex-based differences in outcomes to musculoskeletal and cardiovascular disease devices, as well as devices targeting diseases specific to women. CDRH launched the effort as part of its new “Health of Women” initiative at a June 24-25 workshop.